PD-1/PD-L1拮抗剂在小细胞肺癌治疗中的研究进展  

Research progress of PD-1/PD-L1 antagonist in small cell lung cancer

作　　者：慈倩倩 陈公琰[1] Ci Qianqian;Chen Gongyan(Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院呼吸肿瘤内科,黑龙江哈尔滨150086

出　　处：《现代肿瘤医学》2020年第11期1973-1976,共4页Journal of Modern Oncology

摘　　要：小细胞肺癌是以广泛转移和预后不良为特征的一种恶性肿瘤。虽然34%~85%的小细胞肺癌对化疗有效,但疾病进展迅速,后续的二线治疗效果很不理想,并且近几十年的治疗方案没有突破性进展。近几年生物治疗迅速发展,免疫治疗成为继靶向治疗后的又一次飞跃。程序性死亡蛋白-1(PD-1)与程序性死亡受体-配体1(PD-L1)结合,抑制了CD4^+和CD8^+T细胞的增殖和活化,负性调控机体免疫机制应答过程,从而介导肿瘤细胞的免疫逃逸,促进肿瘤生长。PD-1/PD-L1拮抗剂在SCLC中的临床前及临床研究中均获得了良好效果,让更多的小细胞肺癌患者受益,尽可能的延长生存时间。本文就PD-1/PD-L1拮抗剂在小细胞肺癌中的研究进展作一综述。Small cell lung cancer(SCLC)is a malignant tumor characterized by extensive metastasis and poor prognosis.Although 34%~85%of small cell lung cancer is effective for chemotherapy,the disease progresses rapidly and the follow-up second-line treatment is even less effective.There has been no significant improvement in standard treatment over the last 30 years.The binding of programmed death protein 1(PD-1)to programmed death receptor-ligand 1(PD-L1)inhibits the proliferation and activation of CD4 and CD8 positive T cells,and negatively regulates the immune response of the body,to mediate the immune escape of tumor cells and promote tumor growth.Immunosurveillance site inhibitors,especially programmed cell death receptor-1(PD-1)/programmed cell death ligand-1(PD-L1)antagonists,have achieved good results in preclinical and clinical studies in SCLC,and benefited more patients with small cell lung cancer.This paper reviews the research progress of PD-1/PD-L1 antagonists in SCLC.

关 键 词：小细胞肺癌 程序性死亡蛋白-1(PD-1) 程序性死亡受体-配体1(PD-L1) 

分 类 号：R734.2[医药卫生—肿瘤]